ASPIRES (Activating Cancer Survivors and Their Primary Care Providers to Increase Colorectal Cancer Screening) Study

Last updated: April 24, 2025
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Colorectal Cancer

Colon Cancer

Colon Cancer; Rectal Cancer

Treatment

Primary care provider activation

Control

Patient activation

Clinical Study ID

NCT05084833
STUDY00000296
R01CA255269-01
  • Ages > 30
  • All Genders

Study Summary

The primary purpose of this study is to assess the best method for encouraging high-risk cancer survivors to get screened for colorectal cancer at the recommended age.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Eligible participants will include people who:

  • Enrolled on the Childhood Cancer Survivor Study

  • Were treated with radiation to the abdomen, pelvis, spine, or total body irradiation

  • Have no history of colorectal cancer

  • Have not had a colonoscopy in the last 5 years or Cologuard in the last 3 years

  • Have a smartphone

Exclusion

Exclusion Criteria:

  • Do not reside in the United States

  • Do not speak English

Study Design

Total Participants: 300
Treatment Group(s): 3
Primary Treatment: Primary care provider activation
Phase:
Study Start date:
February 14, 2022
Estimated Completion Date:
November 01, 2025

Study Description

This is a 12-month, 3-arm randomized controlled trial of 315 Childhood Cancer Survivor Study (CCSS) survivors using a text message intervention with data collected at baseline and 12 months through patient and provider surveys and interviews and a medical record review. Participants will be randomly assigned to one of three groups: control, patient activation (PA) using a text message/video intervention, or patient activation + primary care provider activation (PA + PCP) which will include providing primary care providers with resources about colorectal cancer risk in this population. All participants will receive electronic resources about their previous cancer treatment and colorectal cancer screening recommendations.

The primary outcome is the proportion of patients who complete the colonoscopy or Cologuard test (Cologuard test plus colonoscopy if the Cologuard is positive) within 12 months of enrolling on the study, as measured via self-report questions in the end of study questionnaire. The study will test the hypothesis that, compared to controls, survivors randomized to the PA and PA + PCP activation groups will have significantly higher rates of completion of colorectal cancer screening.

Connect with a study center

  • University of Chicago

    Chicago, Illinois 60637
    United States

    Site Not Available

  • Columbia University

    New York, New York 10027
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10017
    United States

    Site Not Available

  • The Pennsylvania State University

    University Park, Pennsylvania 16802
    United States

    Site Not Available

  • St. Jude Children's Research Hospital

    Memphis, Tennessee 38105
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.